What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

Up the stairs to the entrance of the plane they climb: small children with cloudy eyes, teens with thick glasses and practiced squints, adults with dark shades.